Status:
RECRUITING
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia
Lead Sponsor:
Instituto Nacional de Enfermedades Respiratorias
Conditions:
Primary Ciliary Dyskinesia
Eligibility:
All Genders
5+ years
Phase:
NA
Brief Summary
* Patients with primary ciliary dyskinesia (PCD) have trouble with clearing their bronchi from mucus, which in the long-term may produce severe damage to the lungs. Currently, there is no specific tre...
Detailed Description
Background Primary ciliary dyskinesia (PCD) is characterized by ciliary dysfunction causing mucus accumulation in the airways that favors recurrent infections and bronchiectasis. Apart from general ai...
Eligibility Criteria
Inclusion
- Any sex.
- Age of 5 years or more.
- Diagnosis of primary ciliary dyskinesia (PCD) established according to international recommendations (Shapiro et al. Am J Respir Crit Care Med 2018;197(12):e24-e39, and Shapiro et al. Ped Pulmonol 2016;51:115-132).
- Without respiratory exacerbations of PCD in the previous 30 days.
- Without acute respiratory infection in the previous 30 days.
- Informed consent letter signed by the patient (if the patient's age is 18 years or more).
- Informed consent letter signed by the legal guardian, and assent letter signed by the patient (if the patient's age is \<18 years).
Exclusion
- 1\. Participation in other research protocol involving therapeutic measures.
- Elimination Criteria:
- 1\. None.
Key Trial Info
Start Date :
October 2 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06959251
Start Date
October 2 2025
End Date
March 1 2028
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Nacional de Enfermedades Respiratorias
Mexico City, Mexico, 14080